JPMorgan Chase & Co. Acquires 47,873 Shares of Quanterix Co. (NASDAQ:QTRX)

JPMorgan Chase & Co. increased its holdings in Quanterix Co. (NASDAQ:QTRX) by 28.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 217,957 shares of the company’s stock after buying an additional 47,873 shares during the period. JPMorgan Chase & Co. owned 0.57% of Quanterix worth $2,825,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new position in shares of Quanterix during the 3rd quarter valued at about $60,000. Peapack Gladstone Financial Corp purchased a new position in shares of Quanterix during the third quarter worth approximately $131,000. Canada Pension Plan Investment Board bought a new stake in shares of Quanterix in the 2nd quarter worth approximately $140,000. SG Americas Securities LLC purchased a new stake in shares of Quanterix in the 3rd quarter valued at $139,000. Finally, Hsbc Holdings PLC grew its holdings in shares of Quanterix by 34.7% during the 2nd quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock valued at $164,000 after purchasing an additional 3,279 shares during the last quarter. Institutional investors own 86.48% of the company’s stock.

Analysts Set New Price Targets

Separately, TD Cowen boosted their price target on shares of Quanterix from $13.50 to $16.00 and gave the stock a “hold” rating in a research note on Wednesday, November 13th.

Quanterix Price Performance

Shares of Quanterix stock opened at $8.87 on Tuesday. Quanterix Co. has a one year low of $8.21 and a one year high of $29.70. The business’s 50 day simple moving average is $11.18 and its two-hundred day simple moving average is $12.50. The stock has a market capitalization of $341.67 million, a P/E ratio of -8.45 and a beta of 1.33.

Quanterix (NASDAQ:QTRX) last issued its earnings results on Monday, December 23rd. The company reported ($0.22) EPS for the quarter. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. Sell-side analysts expect that Quanterix Co. will post -0.94 earnings per share for the current fiscal year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.